Apnimed receives a Buy rating and $42 price target due to its drug Oxnimbi (AD109) showing positive Phase 3 trial results and an accepted New Drug Application with an FDA decision expected by February 28, 2027. Oxnimbi offers a novel oral treatment for obstructive sleep apnea (OSA), targeting patients who cannot tolerate CPAP devices. The company is financially well-positioned for launch, and the valuation suggests the market undervalues the near-commercial potential of Oxnimbi. Apnimed is highlighted as a top biotech pick for 2027 based on these factors.
Apnimed is featured with a Buy rating and a $42 price target amid its promising drug development. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 00:22 WIB: out of 150 priced US health stocks, 46 rose and 103 fell. Notable movers include LQDA at USD 58.05 with a 1-day change of +5.14% and a typical hold time of 5 days, HRTX at USD 0.34 down 5.09% with a 39-day hold, and IOVA at USD 7.69 down 4.94% with a 6-day hold.
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
